Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Apellis Pharmaceuticals Reports Second-Quarter Loss, Shares Fall


Apellis Pharmaceuticals, a biopharmaceutical company, has announced its second-quarter financial results, causing a 15% drop in the company’s shares. Despite the loss, Apellis reported narrower losses than expected.

Financial Performance

Apellis Pharmaceuticals experienced a quarterly loss of $122 million, or $1.02 per share, compared to a loss of $156 million, or $1.46 per share, in the same quarter last year. Analysts polled by FactSet predicted a loss of $158.6 million, or $1.36 per share.

The company’s revenue for the quarter stood at $95 million, significantly higher than the previous year’s $16.3 million. Product revenue amounted to $89.6 million, exceeding analysts’ expectations of $70.2 million.

Stock Performance

Apellis Pharmaceuticals’ stock hit a 52-week low of $26.60 during the session and has witnessed a 53% decrease over the past 12 months. This decline reflects challenges faced by the company in recent times.

Positive Data from Syfovre Study

Apellis Pharmaceuticals also shared positive data from its extension study of Syfovre pegcetacoplan injection. Syfovre is currently the only FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration.

The study demonstrated the long-term efficacy and safety of Syfovre, showcasing “robust and increasing effects” over 30 months of continuous treatment. Notably, Syfovre managed to reduce GA lesion growth by up to 45% in patients with nonsubfoveal lesions.

Despite the financial loss, Apellis Pharmaceuticals remains well-funded with cash and cash equivalents totaling $616.3 million as of June 30. The company’s financial position is expected to provide sufficient runway into the first quarter of 2025.

Orell Fuessli Reports Lower First-Half Profit

Previous article

Treasury Department to Borrow $1.007 Trillion in Third Quarter

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News